AstraZeneca completed the acquisition of EsoBiotec for $1bn.

AstraZeneca, a global, science-led biopharmaceutical business, completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, for $1bn. As a result of this acquisition, EsoBiotec has become a wholly owned subsidiary of AstraZeneca, with operations in Belgium.